3 Results for "

A-to-I RNA editing

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "A-to-I RNA editing" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-115686
CAS No.: 10299-44-2
Purity:  99.65%
Target:  

Adenosine Deaminase

Research Areas:  

Inflammation/Immunology Cancer

8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells .
loading...
    loading...
Cat. No.: HY-181129
Research Areas:  

Cancer

ADAR1i-124 is an A-to-I RNA editing inhibitor by inhibiting the catalytic activities of both ADAR1p150 and ADAR1p110. ADAR1i-124 activates type I interferon (IFN) and ZBP1 pathways and dose-dependently inhibits viability across different types of cancer cell lines. ADAR1i-124 can induce cells apoptosis and necroptosis. ADAR1i-124 can be used for the research of cancer, such as cutaneous melanoma and ovarian cancer .
loading...
    loading...
Cat. No.: HY-187997
Research Areas:  

Cancer

ADAR1-IN-2 is an adenosine analog and an orally active ADAR1 inhibitor with antiproliferative activity against multiple ADAR1-dependent cancer cell lines. ADAR1-IN-2 inhibits ADAR1-mediated A‑to‑I editing of partial RNA substrates (APOBEC3D), thereby activating the RIG‑I/MDA5‑MAVS signaling pathway, inducing G0/G1 cell cycle arrest and apoptosis in tumor cells, and suppressing tumor cell migration and invasion. ADAR1-IN-2 inhibits tumor growth in DU-145 and HUCCT1 xenograft models. ADAR1-IN-2 can be used in research related to cancers such as prostate cancer and breast cancer .
loading...
    loading...